What are CJC-1295 and Ipamorelin?
CJC-1295 is a synthetic peptide developed to stimulate the release of growth hormone (GH) from the pituitary gland. It is an analog of growth hormone–releasing hormone (GHRH) but modified to have a much longer duration of action. Because growth hormone plays a central role in metabolism, muscle maintenance, fat breakdown, and recovery, CJC-1295 has attracted interest in clinical research.
Ipamorelin is a selective growth hormone secretagogue that works by mimicking a hormone named ghrelin. Ghrelin acts at the anterior pituitary to stimulate GH release without significantly affecting other pituitary hormones. It has gained promise in the research setting for its targeted action and relatively favorable side effect profile.
How Does CJC/Ipamorelin Blend Work?
CJC-1295 and Ipamorelin independently increase growth hormone release; however, they act through distinct receptor pathways — GHRH and ghrelin receptors, respectively — and when combined, produce a synergistic amplification of GH output that exceeds what either peptide achieves alone.
What is CJC (No DAC) / Ipamorelin Blend Used for?
CJC/Ipamorelin Blend has been widely studied in preclinical research. Areas of interest include:
- Age-related GH decline
- Body composition support
- Muscle recovery and repair
- Fat metabolism
- Improving sleep quality
Side Effects of CJC (No DAC) / Ipamorelin Blend
Reported side effects are generally mild and may include injection site reactions, headache, or flushing. Because CJC-1295 stimulates endogenous GH release rather than replacing GH directly, it may carry a lower risk of abnormal hormone levels, though long-term safety data is still limited.
CJC/Ipamorelin Blend Research Dosing Protocol
CJC-1295 comes in two formulations: DAC and no DAC. The no DAC formulation is recommended when combined with ipamorelin, because the two have a similar dosing schedule in a 1:1 ratio. Hence, provided below is the recommended CJC-1295 (No DAC)/Ipamorelin blend dosing schedule.
| Phase | Dose & frequency |
|---|---|
| Week 1 | 0.2 mg daily total (0.1 mg of each component daily) |
| Week 2 | 0.4 mg daily total (0.2 mg of each component daily) |
| Week 3 | 0.6 mg daily total (0.3 mg of each component daily) |
| Weeks 4 and beyond | 0.8 mg daily total (0.4 mg of each component daily) |
Shown for education. A licensed clinician should set any actual dose. Compare protocols across peptides in the peptide dosage chart.
Common questions about CJC-1295 / Ipamorelin blend
What is CJC-1295 / Ipamorelin blend?
CJC-1295 is a synthetic peptide developed to stimulate the release of growth hormone (GH) from the pituitary gland. It is an analog of growth hormone–releasing hormone (GHRH) but modified to have a much longer duration of action.
What is CJC-1295 / Ipamorelin blend used for?
CJC/Ipamorelin Blend has been widely studied in preclinical research. Areas of interest include: Age-related GH decline; Body composition support; Muscle recovery and repair; Fat metabolism; Improving sleep quality.
How does CJC-1295 / Ipamorelin blend work?
CJC-1295 and Ipamorelin independently increase growth hormone release; however, they act through distinct receptor pathways — GHRH and ghrelin receptors, respectively — and when combined, produce a synergistic amplification of GH output that exceeds what either peptide achieves alone.
What are the side effects of CJC-1295 / Ipamorelin blend?
Reported side effects are generally mild and may include injection site reactions, headache, or flushing. Because CJC-1295 stimulates endogenous GH release rather than replacing GH directly, it may carry a lower risk of abnormal hormone levels, though long-term safety data is still limited.
What is the dosage of CJC-1295 / Ipamorelin blend?
One commonly referenced research protocol is: Week 1: 0.2 mg daily total (0.1 mg of each component daily); Week 2: 0.4 mg daily total (0.2 mg of each component daily); Week 3: 0.6 mg daily total (0.3 mg of each component daily); Weeks 4 and beyond: 0.8 mg daily total (0.4 mg of each component daily). Shown for education only; a licensed clinician should set any actual dose. See the dosing table.
How do you mix (reconstitute) CJC-1295 / Ipamorelin blend?
Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.
How much bacteriostatic water do you add to CJC-1295 / Ipamorelin blend?
There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.
Is CJC-1295 / Ipamorelin blend FDA-approved?
No. CJC-1295 / Ipamorelin blend is not FDA-approved in the US (status as of October 2026).
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139:552-61. doi: 10.1530/eje.0.1390552. View source
- Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 May;26:346-60. doi: 10.1210/er.2004-0019. View source
- Fuh VL, et al. Growth hormone secretagogues: mechanism of action and use in aging. Growth Horm IGF Res. 1998 Feb;8:13-20. doi: 10.1016/s1096-6374(98)80317-1. View source
- Giustina A, et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998 Dec;19(6):717-97. doi: 10.1210/edrv.19.6.0353. View source
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. doi: 10.1210/jc.2005-1536. View source